Zai Lab (NASDAQ:ZLAB) is preparing to release its quarterly earnings on Thursday, 2026-02-26. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Zai Lab to report an earnings per share (EPS) of $-0.43.

Investors in Zai Lab are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Historical Earnings Performance

During the last quarter, the company reported an EPS missed by $0.04, leading to a 5.4% drop in the share price on the subsequent day.

Here's a look at Zai Lab's past performance and the resulting price change:

Performance of Zai Lab Shares

Shares of Zai Lab were trading at $19.37 as of February 24. Over the last 52-week period, shares are down 44.28%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

All You Need to Know About Zai Lab

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

A Deep Dive into Zai Lab's Financials

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Positive Revenue Trend: Examining Zai Lab's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.52% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Zai Lab's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -30.98% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Zai Lab's ROE stands out, surpassing industry averages. With an impressive ROE of -4.64%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Zai Lab's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.1% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Zai Lab's debt-to-equity ratio is below the industry average. With a ratio of 0.29, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

To track all earnings releases for Zai Lab visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.